Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study

Area of Science:

• Hepatobiliary cancers
• Oncology
• Cancer epidemiology

Background:

• Fibrolamellar hepatocellular carcinoma (FLC) is a rare subtype of hepatocellular carcinoma (HCC), accounting for 1-2% of cases in the USA.
• FLC remains poorly understood, necessitating further investigation into its characteristics and patient outcomes.

Purpose of the Study:

• To investigate the incidence, demographics, tumor characteristics, treatment modalities, and prognosis of patients diagnosed with FLC.
• To compare the survival outcomes of FLC with those of standard HCC.

Main Methods:

• Utilized data from the Surveillance, Epidemiology, and End Results (SEER) database for FLC cases diagnosed between 2000 and 2016.
• Analyzed a cohort of 300 FLC patients to determine incidence rates, demographic factors, tumor staging, treatment patterns, and survival statistics.

Main Results:

• FLC incidence was 0.02 per 100,000 person-years, with a bimodal distribution peaking in adolescents/young adults (15-19 years) and older adults (70-74 years).
• Surgical resection was performed in 50.3% of cases; chemotherapy and radiation were less common and did not significantly impact outcomes.
• One- and 5-year survival rates were 72.0% and 32.9%, respectively, with a median survival of 32.9 months, significantly longer than HCC's median survival of 11.7 months.

Conclusions:

• FLC exhibits a unique bimodal age distribution and presents differently from typical HCC.
• While FLC has a higher recurrence rate than HCC, it demonstrates a better overall survival outcome.
• Surgical intervention is the most effective treatment for FLC, yielding superior results compared to chemotherapy or radiation therapy.